NCT05497284 - To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

August 26, 2024

Study Completion Date

September 26, 2024

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

LTP001

LTP001 administered once daily in the morning

DRUG

Placebo

Placebo to LTP001 administered once daily in the morning

DRUG

Standard of Care (SoC)

nintedanib, pirfenidone, or neither

Trial Locations (15)

1884

Novartis Investigative Site, Ranelagh Partido de Berazate

2050

Novartis Investigative Site, Camperdown

3100

Novartis Investigative Site, Paraná

4032

Novartis Investigative Site, Chermside

6163

Novartis Investigative Site, Spearwood

35294

University of Alabama at Birmingham, Birmingham

45147

Novartis Investigative Site, Essen

66160

University of Kansas Hospital, Kansas City

81377

Novartis Investigative Site, Munich

C1056ABJ

Novartis Investigative Site, CABA

140 59

Novartis Investigative Site, Prague

01640

Novartis Investigative Site, Coswig

1081 HV

Novartis Investigative Site, Amsterdam

3435 CM

Novartis Investigative Site, Nieuwegein

15-044

Novartis Investigative Site, Bialystok